1,001

Re: OMEROS (OMER) - Main Corporate Thread

The other day, very shortly after the results of the Meeting election that approved the new employee bonus option plan, Omeros filed a registration statement for the share.

I think they purposely did this quickly.
While it may just be efficiency, it also may be because OMER will soon make the option awards.

I suspect that because I suspect they will want to tie the options to as low a share price as possible, so that they all make a lot more money. Getting options at $15 is so much nicer than getting them at $25 after the results of the ISPY trial is announced (as an example).

I do not know this is the case, but they always like to have a low strike price because it makes the options worth much more.

So....if they announce the option grants we may consider it a hint that good news should be coming soon. Of course, that could be wrong, but the grants would increase the probability that the expectation was correct... and all wehave to play is probabilities when trying to project what will happen in the future.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,002

Re: OMEROS (OMER) - Main Corporate Thread

https://charts.stocktwits.com/production/original_345463674.jpg

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,003

Re: OMEROS (OMER) - Main Corporate Thread

Steve Brozak raised OMER target to $100 from $75 and added a BUY reccomendation.

So now it  is
BUY 2
Outperform 4
Hold 2

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,004 (edited by sbeal 2021-06-18 09:12:23)

Re: OMEROS (OMER) - Main Corporate Thread

So i guess a price target of 75 on a 15 stock didnt merit a buy recommendation?

1,005

Re: OMEROS (OMER) - Main Corporate Thread

Steve is bold!  smile

1,006

Re: OMEROS (OMER) - Main Corporate Thread

The $75 was made years ago and then he seems to stop coverage. Have not seen a report from him in over a year.

It could have been Outperform. I do not recall.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,007

Re: OMEROS (OMER) - Main Corporate Thread

Look at Brozak's bio and you can see why he can make bold calls.

He's the boss at WBB Securities.
He's been a CEO of Storm Bio trying to reduce cytokine storm in viruses.
He was a Lt. Col in the Marines.

https://en.wikipedia.org/wiki/Steve_Brozak
He doesn't have to worry about his job.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,008

Re: OMEROS (OMER) - Main Corporate Thread

Another 200,000 share covered at the open this morning.
Not showing on the volume because likely done off-market in dark pool arranged transaction.
Available to borrow went up that amount is how we know.

The large amount of short covering lately seems to be in these off-market venues and not related to transactions in the Notes.

It make sense that BIG shorts have sources in ISPY because they don't want to be massively short when OMER is announced to be the first success in the trial.

We can't be sure, but this kind of stuff bolsters my analysis that there is already enough proof to know, based upon the Bergamo results.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,009 (edited by Jim Burns 2021-06-18 11:42:23)

Re: OMEROS (OMER) - Main Corporate Thread

I had a small position in OMER bought at 15.00, got weary of nothing happening, so I sold it first thing this morning at 15.45 that must have been scooped up by the dark pool you mentioned because all the quote services show a daily high of only 15.30.

Will buy back at 14.00 if it falls to there.

1,010

Re: OMEROS (OMER) - Main Corporate Thread

You must have sold it premarket, I'd bet.
This morning there were over 3000 that sold premarket and almost all was 15.20 and higher.

So it could have been related to the dark pool.
In the old days, dark pool trades were just deals between large institutional buyers and sellers that were negotiated öff market". IOW, someone with a Million PFE wants to sell without pushing the price down, so they ask for expressions of interest through their broker.... whose Institutional traders/desk calls up companies who they think might want to buy at a bit of a discount on the current price. After the parties agree on the discount they cross the shares, now without reporting it to any market. They do have to file with the SEC though if it is reportable because of their status, etc.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,011

Re: OMEROS (OMER) - Main Corporate Thread

The Fly has a comment from Brozak

Omeros price target raised to $100 from $75 at WBB Securities WBB Securities analyst Steve Brozak raised the firm's price target on Omeros to $100 from $75 and reiterates a Strong Buy rating on the shares. The analyst says the narsoplimab approval "will be a game changer" for the company. Omeros' continued progress implementing an approved drug and advancing a second one toward FDA and European approval "are the earmarks of the progression into a major biopharmaceutical franchise," Brozak tells investors in a research note.

Read more at:
https://thefly.com/n.php?id=3322751

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,012 (edited by sbeal 2021-06-18 12:47:56)

Re: OMEROS (OMER) - Main Corporate Thread

greenguy wrote:

Steve is bold!  smile

And i thought you were commenting on my post! smile

1,013

Re: OMEROS (OMER) - Main Corporate Thread

This statement is true:
Steve is bold

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,014

Re: OMEROS (OMER) - Main Corporate Thread

Did you see all the late volume on this??????
ended at 950K and only 125k from 4pm on.
FISHY

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,015

Re: OMEROS (OMER) - Main Corporate Thread

After hours trading up to 15.37….somebody accumulating?

1,016 (edited by greenguy 2021-06-18 17:46:32)

Re: OMEROS (OMER) - Main Corporate Thread

Just 4 shares at $15.37 .......... sad

1,017

Re: OMEROS (OMER) - Main Corporate Thread

The high volume today could be options-expiration related

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,018

Re: OMEROS (OMER) - Main Corporate Thread

Over half (393,350 shares) of OMER trading today came in the last minute.

1,019

Re: OMEROS (OMER) - Main Corporate Thread

Volume AH was also high and unusual.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,020

Re: OMEROS (OMER) - Main Corporate Thread

Brokerages Anticipate Omeros Co. (NASDAQ:OMER) to Announce -$0.50 Earnings Per Share

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,021

Re: OMEROS (OMER) - Main Corporate Thread

At this time yesterday, volume was barely 100k shares. The decline could be attributed to lack of bids.
Now >430k  volume suggest more active selling.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,022

Re: OMEROS (OMER) - Main Corporate Thread

Up 77 cents after hours.  Explanation?

1,023

Re: OMEROS (OMER) - Main Corporate Thread

A poor Picasso (actually a few of them possibly), making tiny buys. Last was at $15.10.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,024

Re: OMEROS (OMER) - Main Corporate Thread

REDDIT??? wild swings today

https://api.wsj.net/api/kaavio/charts/big.chart?nosettings=1&symb=omer&uf=0&type=2&size=2&sid=3942233&style=320&freq=9&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=1&rand=618526275&compidx=aaaaa%3a0&ma=0&maval=9&lf=1&lf2=0&lf3=0&height=335&width=579&mocktick=1

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,025

Re: OMEROS (OMER) - Main Corporate Thread

CRISPR, Omeros among “actionable” SMID-cap biopharma for H2 2021 at BofA

Jul. 02, 2021 2:10 PM ETCRSP, KNSA...By: Dulan Lokuwithana, SA News Editor4 Comments

Bank of America has listed CRISPR Therapeutics (CRSP -0.7%), Omeros Corporation (OMER -4.4%), Kiniksa Pharma (KNSA -2.4%), and PMV Pharma (PMVP -0.6%) as actionable small and mid-cap biopharma companies with key updates in H2 2021.
The analysts led by Geoff Meacham argue that CRISPR’s clinical program for sickle cell disease and beta-thalassemia “is already largely de-risked.” However, they expect further momentum for shares as the company reveals more data/filing plans.
The firm also highlights the upcoming data readout from CRISPR’s CAR-T program expected in H2 2021. In 2021, the company expects to announce data from phase 1 trials for CAR-T candidates CTX130 and CTX110 in R/R B-cell malignancies and solid tumors/ hematologic malignancies, respectively.
The analysts also point out, “Omeros is positioned for its first narsoplimab approval.” The marketing application filed by the company for FDA approval for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA or TA-TMA) has the FDA action date on October 17.
On Kiniksa, Meacham and the team highlight the recent launch of Arcalyst, which according to them, “could surprise to the upside” given their $20M estimate for sales in 2021 compared to $17M in consensus. In March, the FDA approved Arcalyst (rilonacept) for recurrent pericarditis.
PMV Pharma’s early-stage data in solid tumors for PC14586 are expected later this year, the analysts point out with a prediction “that could help re-rate” the company shares.
In April, PMV Pharma disclosed preclinical data for PC14586 at the American Association for Cancer Research (AACR) Annual Meeting 2021, indicating the ability of the small molecule to selectively reactivate the p53 Y220C mutant protein, which is linked to many cancers.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,026

Re: OMEROS (OMER) - Main Corporate Thread

There were 361 TI website hits on the new article in the Omeros section, in the first 24 hours.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,027

Re: OMEROS (OMER) - Main Corporate Thread

Another SA article on OMER
https://seekingalpha.com/article/443773 … pportunity
Here is the text without the illustrations.

Omeros: PDUFA Delay Presents An Opportunity
Jul. 03, 2021 10:45 AM ETOmeros Corporation (OMER)4 Comments2 Likes
Avisol Capital Partners
http://avisolcapital.com
Long/Short Equity, Healthcare, Biotech
Contributor Since 2017

Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.

Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.
If you want to check out our service, go here - https://seekingalpha.com/author/avisol- … s/research
Disclaimer - we are not investment advisors.

Summary
Omeros has had its PDUFA delayed by three months.
The reason is that the FDA needs additional time to review data it had asked for.
This represents a buying opportunity.
Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »
I left off Omeros (OMER) in February 2019. At that time, it was running a phase 3 trial in HSCT-TMA for OMS721/narsoplimab, and was in ongoing discussions with the FDA about whether it could abandon historical controls or comparative data and simply look at response-based primary endpoints for its trial. A few months down the line, the FDA approved a response-based primary endpoint. Then, in September 2019, the company started a rolling BLA application with the FDA under a priority review. In August, OMER jumped 50% after reporting positive data from a trial of narsoplimab in Covid-19 patients with ARDS. The rolling BLA was finally completed in November 2020, a month after producing final efficacy and safety data from the pivotal trial. In January, the FDA accepted the company’s BLA and set a PDUFA date of July 17, 2021.

However, then everything got stuck. In May, the FDA extended the PDUFA date to October 17 to review additional material the company had presented in response to questions asked by the FDA. We do not know the nature of these questions. The stock currently trades at $15, and its 52-week high is $24. Is it a buy?

I came across a quote from the BofA report, source unverified, as follows:

"Recall that the narsoplimab rolling BLA was submitted at the request of FDA, with the understanding that data from the 28 patients treated was sufficient as a pivotal study. Given that the data were very strong, we don’t see the delay as likely to be due to any specific issue with narsoplimab, rather in our view it is more likely a consequence of FDA being thorough in the review as narsoplimab would be the first treatment approved in this indication."

Although the source is unverified, the logic makes sense. The FDA were very agreeable with Omeros throughout, agreeing to a response-based endpoint, agreeing to cut enrollment short after positive data from already-enrolled patients, approving a rolling BLA, approving a single arm phase 2 trial to become pivotal, and so on. BofA has been consistently bullish on Omeros over the years, but what this says here does make sense.

Management, too, sounded confident. They generally do, until calamity strikes; sometimes even afterwards. However, here’s what the CEO said:

“We’re pleased with our ongoing interactions with FDA on the narsoplimab BLA,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “Omeros views the information provided in response to FDA’s information request as further supporting the application, and we look forward to making narsoplimab available to HSCT-TMA patients and their physicians as soon as possible.”

The FDA has also not shown any indication of holding an advisory committee meeting, which, given the delay, is actually a positive signal. It is my reading that the FDA prefers to hold these meetings in controversial situations. I don’t want to use the word “slam dunk,” however the FDA would have held an adcomm if it had doubts about the BLA, and if such doubts had led to the information request.

Quickly recall the data in these two charts:



Source

I have discussed historical and comparative data in my previous coverage. There are no approved treatments, and this is a very high risk, severely ill population of patients. In this population, such a dataset is outstanding. The drug was also well-tolerated.

The size of the addressable market is decent. There are 25,000-30,000 allogeneic HSCT patients in the US and EU combined, every year. The following chart from the company’s Corporate Presentation shows how the market lies:



Source

HSCT-TMA causes extensive hospital stays, and is often fatal; this represents a high burden on the healthcare system. As I wrote in my previous article:

Between the US and the EU, over 60,000 HSCT treatments are performed every year (2015 figures, see Omeros Corporate Presentation). 40% of these, or 24,000, develop TMA, and 80% of that, or 19,200, have high-risk features. Out of these 19,200, 17,280 or 90% could be looking at mortal complications; even those that survive may develop ESRD or end-stage renal disease. This is the target market for OMS721 in HSCT-TMA. The US has about 4,000 patient incidence rate for HSCT-TMA per year.

Current treatment options are not FDA approved, and do not target the disease. “Some of the currently used treatment options include removing the calcineurin inhibitors (CNIs, used during HSCT), controlling the associated complications without directly targeting the disease, as well as therapeutic options like plasma exchange, defibrotide, rituximab and eculizumab (soliris).” The nearest competition seems to be from Alexion’s (ALXN) ravulizumab, which is running a phase 3 trial in the indication, to be completed in mid-2023.

Financials
OMER has a market cap of $925mn, a cash reserve of $100mn, debt of $300mn and a short interest of 21%. The company has a moderate institutional/fund presence, who own about 60% of the stock. However, funds have generally been bullish, increasing positions or new funds adding the stock to their portfolios:
Source

Major holders are:
Source

However, like before, insiders have not been buying:
Source

Bottomline
OMER has always been a beleaguered stock. The high short interest, and the general chatter on social media, proves that. The stock is trading quite low right now, and given the upcoming catalyst, the large market, the high unmet burden, and solid data, this looks like a cautious buying opportunity.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,028

Re: OMEROS (OMER) - Main Corporate Thread

He gushes about OMER throughout the article, but in the end takes the chickenshit way out by saying OMER is a “cautious buying opportunity.”

1,029

Re: OMEROS (OMER) - Main Corporate Thread

and at the very start, this is wrong

I left off Omeros (OMER) in February 2019. At that time, it was running a phase 3 trial in HSCT-TMA for OMS721/narsoplimab, and was in ongoing discussions with the FDA about whether it could abandon historical controls or comparative data and simply look at response-based primary endpoints for its trial.

The FDA has NOT required a Phase 3 trial.
To do a Phase 3 trial, you kind of need an end of Phase 2 trial and permission to do a Phase 3.
The point about the FDA being eager to approve Omeros is that the DURING Phase 2 trial ended up getting permission to BE the equivalent of a Phase 2 trial.

It is like Omeros was going to high school and was in 11th grade. In December it met with the Academic Dean and the Dean was so impressed they discuss Omeros' achievement. The Dean said, if you just complete the classes you are in now, you can start applying to colleges right away. You don't have to start your Senior year, here, your knowledge and ability are enough to warrant that you go right into College.

Keep in mind that Seeking Alpha forces you to not take a categorical stance, even if that is your opinion.
That's why I refused to make changes they said I had to make and published in an unedited Blog and stopped publishing there (except in Blogs very infrequently).

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,030

Re: OMEROS (OMER) - Main Corporate Thread

3 more Form 4s filed.
75k options at $14.99 for Cancelmo and Jacobsen
and 550k for Greg.

The filings indicate that these guys have NO OTHER OPTIONS, other than these new ones.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,031

Re: OMEROS (OMER) - Main Corporate Thread

Comments from Needham

Omeros Corporation (OMER) – Hold

■An FDA delay pushed Narsoplimab's PDUFA from 7/17/2021 to 10/17/21, thus investor focus is likely to center on commercial launchprep activities and ongoing interactions with FDA.

■Besides narsoplimab, the other OMER value driver is Omidria sales, which are expected to return to prior annual levels of >$100MM.1Q21 Omidria sales were slighlty below expectations due to delayd reimbursement procedures and linging Covid impacts on cataractsurgery volumes.

■OMER ended 1Q21 with cash of ~$101MM, which should provide runway into early-2022. The company has since entered into aATM  sales  agreement  allowing  the  company  to  raise  up  to  $150MM  in  equity.  Additional  capital  will  be  required  to  fund  thenarsoplimab launch and other development programs.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,032

Re: OMEROS (OMER) - Main Corporate Thread

The number of hits on the ISPY article is up to 680 now and I have not done any posting of the URL since posting it on the 6th.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,033

Re: OMEROS (OMER) - Main Corporate Thread

see http://www.trustintelligence.com/viewto … 8187#p8187

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,034

Re: OMEROS (OMER) - Main Corporate Thread

Here is the kind of crap analysis that people investigating Omeros get to read from incompetant bot-analysts, like Zacks. I am, and have been, distressed that Interactive Brokers features Zacks' "crapanalysis". The article below is a Zacks copycat, so it is just as bad or possibly worse. The wide variation in the quoted analysts are not going to help people want to buy Omeros. Why Zacks, with a SELL is given more play when the consensus is said to be a BUY, I cannot explain.

In Q1'21 OMER lost 57 cents. If Omidria revenue is what I estimated (a bit more than $34M), the loss for Q2'21 will decline by about 15 cents to $0.42. More importantly, the cash burn will be only about $15M ofr Q2 and that will leave cash of about $85M.

With continuing Omidria progress, cash at the end of Sept. will be ~$70M just ahead as the scheduled PDUFA date in October. Of course, if Omeros wisely increases the amount of narsoplimab it is buying so that it can sell more for CV19, the amount of cash on hand will be less than I am projecting.

That is why it is important for OMER to know, for sure, what the ISPY trials are doing and when it will read out. Good ISPY is NOT going to result in immediate need for more narso to treat patients. We do not know that OMER is already at work on an EUA, although I would have already prepared the parts about the drug, the CUP data, and other supporting information, so all that is needed is to add in the ISPY data. Even with this unheard of efficacy, the FDA will not approve an EUA in a week or two, although they should. It will probably take a week or two to read the application!

It will cost more money to launch narso for TA-TMA and we can expect a positive report from ISPY to move the price higher, temporarily, giving OMER a chance to use the Cantor ATM to raise more cash. But this will have a cost of blunting the market rise caused by greater recognition that narso can save the lives of severe CV19 patients.
======================
-$0.50 EPS Expected for Omeros Co. (NASDAQ:OMER) This Quarter
Posted by Ethan Ryder on Jul 22nd, 2021

Omeros Analysts expect Omeros Co. (NASDAQ:OMER) to post earnings of ($0.50) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Omeros’ earnings, with the highest EPS estimate coming in at ($0.44) and the lowest estimate coming in at ($0.56). Omeros reported earnings per share of ($0.48) in the same quarter last year, which indicates a negative year-over-year growth rate of 4.2%. The business is expected to report its next earnings report on Monday, August 9th.

According to Zacks, analysts expect that Omeros will report full-year earnings of ($2.18) per share for the current fiscal year, with EPS estimates ranging from ($2.21) to ($2.16). For the next fiscal year, analysts expect that the business will report earnings of ($1.75) per share, with EPS estimates ranging from ($2.57) to ($1.28). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Omeros.

Get Omeros alerts:
Enter Your Email Address
Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Sunday, May 9th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.57). The business had revenue of $21.10 million during the quarter, compared to analysts’ expectations of $21.96 million. The business’s quarterly revenue was down 10.6% compared to the same quarter last year.

A number of analysts recently commented on the company. Zacks Investment Research cut Omeros from a “hold” rating to a “sell” rating in a research report on Thursday, July 8th. HC Wainwright reduced their price target on Omeros from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Monday, April 26th. Finally, WBB Securities upped their price target on Omeros from $75.00 to $100.00 and gave the stock a “strong-buy” rating in a research report on Friday, June 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $33.57.
In other Omeros news, CEO Gregory A. Md Demopulos sold 36,857 shares of Omeros stock in a transaction dated Thursday, June 17th. The stock was sold at an average price of $14.90, for a total transaction of $549,169.30. Following the completion of the sale, the chief executive officer now owns 2,063,842 shares of the company’s stock, valued at approximately $30,751,245.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Gregory A. Md Demopulos sold 36,856 shares of Omeros stock in a transaction dated Tuesday, June 15th. The shares were sold at an average price of $15.02, for a total value of $553,577.12. Following the transaction, the chief executive officer now owns 2,063,842 shares of the company’s stock, valued at approximately $30,998,906.84. The disclosure for this sale can be found here. Corporate insiders own 9.90% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMER. Capital Analysts LLC acquired a new position in Omeros in the first quarter valued at $36,000. Wolverine Asset Management LLC acquired a new stake in shares of Omeros during the first quarter worth about $89,000. Quantbot Technologies LP boosted its stake in shares of Omeros by 363.3% during the first quarter. Quantbot Technologies LP now owns 5,078 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 3,982 shares during the period. Creative Financial Designs Inc. ADV purchased a new position in Omeros during the first quarter worth about $91,000. Finally, Arkadios Wealth Advisors raised its holdings in Omeros by 460.0% during the first quarter. Arkadios Wealth Advisors now owns 5,600 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 4,600 shares in the last quarter. Hedge funds and other institutional investors own 55.39% of the company’s stock.

Omeros stock opened at $14.37 on Monday. Omeros has a one year low of $9.25 and a one year high of $25.46. The firm’s fifty day moving average price is $15.34.

Omeros Company Profile

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,035 (edited by Jim Burns 2021-07-23 10:41:42)

Re: OMEROS (OMER) - Main Corporate Thread

I get the Zacks analysis on various stocks all the time on Yahoo Finance, they are worse than "crapanalysis," they are devoid of usable real world facts, especially for companies like OMER operating at a loss but with good future prospects.  The Zacks analyses are just a way to get your email address so they can sell it to others and/or entice you into buying their products which are probably junk as well.

1,036

Re: OMEROS (OMER) - Main Corporate Thread

Yup, Zacks just exploits the novice investor who doesn't know any better... and there is always a bumper crop.
=====================

Here is an interesting case study that relates to OMER in 2 ways.
1. The company is trying to develop a drug in wet AMD and Omeros's complement drugs will probably help or cure wet AMD once they are in PILL form in 2 to 3 years.
2. The oral history of OMER suggests that one of the preceding and triggering events for OMER, that led to it being targeted by the Fidelity owner/management private hedge fund, as Baker Brothers wanting a sweetheart deal from Greg. IOW, Baker Brothers wanted inside information in return for sponsorship, and I presume they would put in money in some way. The story goes that Greg rejected their Offer and Baker Brothers were pissed off. Again, as the story goes, they approached Fidelity's hedge fund and suggested they gang up on OMER to exploit them via shorting... Fidelity took a look and thanked the Baker boys and told them to lay off...Fido would do it themselves.

So this story is about a new company who took Baker $$$ and then made progress and raised a huge amount on their own, and now has refused to continue with the step 2 of their original deal. In hindsight, if OMER could have gotten huge money and a high share price that allowed them to raise even more money, before telling Baker to take a hike Omeros might have been much better off and have a $50+ share price now, before narso approval.
But who can really be sure of what would have happen if the path NOT taken was Taken?
====================================
Kodiak turns down $125M payment from Baker Bros. deal, slashes royalty cap by 55%
Max Gelman Editor
Endpoints
Following a massive public raise last November, Kodiak Sciences has re-worked a royalty sale agreement with an old partner — and declined new funds in the process.

Kodiak is turning down a planned $125 million payment from Baker Bros. Advisors, according to an SEC filing, cutting short an agreement that saw the biotech hand over a 4.5% stream of royalty sales on its experimental anti-VEGF therapy KSI-301 for retinal vascular diseases. In conjunction with the move, Kodiak is shrinking the royalty cap from just over $1 billion to $450 million.

Endpoints News has reached out for comment and will update accordingly.

The deal called for Baker Bros. to pay $225 million to Kodiak in two installments, the first of which came as a payment of $100 million back in early 2020. The remaining $125 million, which Kodiak declined Thursday, was originally expected to come sometime in late 2020 once Kodiak had reached at least 50% enrollment in two pivotal clinical studies for KSI-301.

Kodiak reached the expected milestones but turned down the payments anyway, per the 8-K report. The biotech claims its “strong balance sheet” following a November public offering that raised $612 million provided the motivation for turning down the extra $125 million, in addition to “clinical trial progress and capital resources.”

At the time, the move represented a hefty wager for Baker Bros., putting down the cash just a couple months after Kodiak launched its first clinical trial for wet AMD. It’s a strategy the firm had employed in other investments as well, chipping in early to Amarin and a biotech developing a rival for its Vascepa drug, Matinas BioPharma.

Since then, however, Kodiak has vastly expanded their clinical program for KSI-301. In the summer of 2020, the biotech launched two Phase III trials for the candidate in diabetic macular edema, as well as a third study in retinal vein occlusion. Data are expected for each study by the end of 2021.

Kodiak is also planning to start recruiting for another Phase III study in non-proliferative diabetic retinopathy this summer. And execs are expecting to build out further data for the wet AMD indication, plotting a separate study here for treatment-naïve patients. Recruitment here will also start this summer and Kodiak has said it will include these data in its initial FDA filing.

Should the candidate eventually be approved, Kodiak would aim to chase down a market led by the Regeneron blockbuster Eylea. Kodiak will be competing with some big names in pharma to carve up that pie, however, as Novartis and Roche are each wading into the scene with their own drugs.

As the Palo Alto, CA-based biotech sets the scene for these data to drop in succession, it’s similar to the time in which the royalty deal was originally signed. Just one day after nailing down that deal, Kodiak began offering $250 million worth of shares on the public market.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,037

Re: OMEROS (OMER) - Main Corporate Thread

At 14:54 in the July 22nd podcast on this page (scroll down to the correct date):
https://thedrilldown.podbean.com/

The Drill Down is a daily podcast focused on business fundamentals of the biggest stock movers of the market day, hosted by veteran financial journalist Cory Johnson. Through insightful interviews with CEOs and investors, meaningful research and in-depth analysis, The Drill Down provides a clearer picture of what’s really going on under the hood at publicly traded companies. This is business news for business people.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,038

Re: OMEROS (OMER) - Main Corporate Thread

great discussion!
and no reaction on friday?

1,039

Re: OMEROS (OMER) - Main Corporate Thread

Very low volume on Friday.
In the summer, many take Friday off and go to the cottage....

Plus, people/institutions, who are long-term investors will do some due diligence after they find something interesting, so the reaction can be delayed.

Not the conversation contained warnings that act as disclaimers to prevent law suits, or at least provide a plausible defense.
There are a lot of idiots out there.

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.

1,040

Re: OMEROS (OMER) - Main Corporate Thread

Omeros hopes to sooner or later call the Notes and pay them off to preclude conversion into shares. I cam across a document that explains convertible notes AND the ways that institutions tend to go short to protect their value., like they do with Omeros.

http://documents.jdsupra.com/cbd08f1e-9 … e4c463.pdf

original content ©2020 to 2021 by Alan Robert Ross
Founder, Trust Intelligence
The foregoing is not investment advice.